- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Communicable diseases such as HIV, TB and malaria remain among the leading causes of illness, death and impoverishment in our region, and infection levels continue to rise in many settings and populations. Unless focused efforts are undertaken to build on the gains to date, communities that remain vulnerable to neglected tropical diseases such as leprosy, kala-azar and filariasis will continue to be left behind. This report focuses on the historic opportunity for the WHO South-East Asia Region to end the scourge of communicable diseases for good.
Keywords: HIV, TB, malaria, neglected tropical diseases, public health
The World Health Organization (WHO) is committed to ensuring that the great success of HIV treatment scale-up is not threatened by HIV drug resistance (HIVDR). Preventing HIVDR is an important part of meeting the 90-90-90 targets by the year 2020.
The development of a five-year plan reflects a global consensus that HIVDR in lower and middle-income countries requires a coordinated and resourced response. The Global Action Plan is an agreement by key partners about their respective roles in preventing, monitoring, and responding to HIVDR.
Syphilis, a sexually transmitted bacterial infection, affects almost 40 million people worldwide. Like HIV, it can be passed from a pregnant woman to her unborn child. In pregnancy, if untreated, syphilis can result in severe outcomes for mother and infant. Yet, transmission can be effectively prevented with inexpensive and easily available penicillin treatment for pregnant women.6 Recognizing the opportunity to test and treat mothers and babies during antenatal or perinatal care, in 2007, the WHO and its partners published the Global elimination of congenital syphilis: rationale and strategy for action. The goal was to increase the number of pregnant women tested for syphilis to 90 per cent and to provide adequate treatment to at least 90 per cent of seropositive pregnant women by 2015.
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome. It also provides information on the production of new hepatitis C drugs and generic versions worldwide, including where the drugs are registered, where the drugs are patented and where not, and what opportunities countries have under the license agreements that were signed by some companies as well as current pricing of all recommended DAAs, including by generic companies all over the world.
Keywords: HIV, hepatitis C, HCV, treatment, diagnosis, testing
With increasing global use of antiretroviral therapy (ART) to both treat and prevent HIV, and increasing global trends in HIV drug resistance ( HIVDR), efforts to improve HIV programme quality and prevent the emergence and transmission of drug-resistant HIV must be strengthened.
This global report is based on 59 countries that reported data from more than 12 000 clinics from cohorts of patients receiving ART between 2004 and 2014. The report includes the most recent clinic-level data reported to WHO in 2015 –2016 and reflects a lag due to the 12 month cohort reporting period.
All babies have the right to a healthy start in life.
Every year, approximately 1.5 million HIV-positive women give birth. If they are unable to access medicine and services, they run the risk of transmitting HIV to their babies during pregnancy, delivery and the breastfeeding period.
Now, with only one pill a day started during pregnancy, along with delivery in a medical facility by a skilled health professional and continued treatment through the breastfeeding period, advances in antenatal care mean that the risk of HIV transmission from mother to baby can be virtually eliminated.
The present document aims to review the progress of the HIV response in the Asia-Pacific region, with a view to identifying the opportunities for further action afforded by the 2011 Political Declaration. In doing so, it also draws on the expressed commitments undertaken by ESCAP member States to address the HIV epidemic, including those reflected in resolutions 66/10, Regional call for action to achieve universal access to HIV prevention, treatment, care and support in Asia and the Pacific (19 May 2010) and 67/9, Asia-Pacific regional review of the progress achieved in realizing the Declaration of Commitment on HIV/AIDS and the Political Declaration on HIV/AIDS (25 May 2011).
Keywords: IGM, 2015, HIV, prevalence, treatment, care, prevention, gender, violence, ART, children, women
The 10 case studies presented in this document clearly demonstrate that social protection works for HIV prevention, treatment, care and support. In particular, they show how social protection benefits the AIDS response through increased access to HIV services for all people including the most marginalized and excluded in society. The studies also demonstrate that carefully constructed and well-managed social protection programmes have the power to support people who are hardest to reach.
The world faces an important window of opportunity in the trajectory of the global AIDS response. New scientific evidence shows that starting HIV treatment immediately upon diagnosis enables people to live longer, healthier lives and is among the most effective ways to prevent HIV transmission. Several years ago, in response to this evidence, some countries began providing all people living with HIV access to immediate treatment.
The purpose of this manual is to provide guidance to public health professionals tasked with managing a response to viral hepatitis. As every country’s needs are different with respect to its epidemiology and the current level of response, people would use this manual in different ways.